These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin. MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200 [TBL] [Abstract][Full Text] [Related]
4. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival. McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909 [TBL] [Abstract][Full Text] [Related]
5. BCG immunotherapy in previously treated malignant melanoma patients. Mujagić H; Kolarić K; Malenica B; Nola P Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant BCG immunotherapy for stage I and II malignant melanoma. Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739 [TBL] [Abstract][Full Text] [Related]
7. [Development in the immunotherapy of malignant melanoma]. Tritsch H Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300 [TBL] [Abstract][Full Text] [Related]
8. Combined immunotherapy in malignant melanoma. Regression of metastatic lesions in two patients concordant in timing with systemic administration of transfer factor and Bacillus Calmette-Guérin. Spitler LE; Levin AS; Wybran J Cell Immunol; 1976 Jan; 21(1):1-19. PubMed ID: 764975 [No Abstract] [Full Text] [Related]
10. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma. Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970 [TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy. Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094 [TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy. Richman SP; Gutterman JU; Hersh EM Can Med Assoc J; 1979 Feb; 120(3):322-4, 329. PubMed ID: 371776 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of malignant disease (Part 2). MacGregor AB; Falk RE J R Coll Surg Edinb; 1976 Jan; 21(1):43-9. PubMed ID: 765453 [No Abstract] [Full Text] [Related]
14. Immunotherapy in malignant melanomaa. Homes EC; Morton DL; Eilber FR; Golub SE; Sulit HL Natl Cancer Inst Monogr; 1976 Nov; 44():85-6. PubMed ID: 799763 [TBL] [Abstract][Full Text] [Related]
15. Multimodality therapy in the treatment of regionally inoperable melanomas and sarcomas. Yeager RA; Eidemiller LR; Fletcher WS Surg Gynecol Obstet; 1975 Sep; 141(3):367-70. PubMed ID: 1162562 [TBL] [Abstract][Full Text] [Related]
16. Surgical treatment of malignant melanoma. Rosenberg SA Cancer Treat Rep; 1976 Feb; 60(2):159-63. PubMed ID: 769968 [TBL] [Abstract][Full Text] [Related]
17. Metastasectomy and active specific immunotherapy for a large single melanoma metastasis. Baars A; van Riel JM; Cuesta MA; Jaspars EH; Pinedo HM; van den Eertwegh AJ Hepatogastroenterology; 2002; 49(45):691-3. PubMed ID: 12063971 [TBL] [Abstract][Full Text] [Related]